-+ 0.00%
-+ 0.00%
-+ 0.00%

Klaria Pharma issues correction to Q2 2026 interim report

PUBT·08/31/2026 22:31:47
Listen to the news
Klaria Pharma issues correction to Q2 2026 interim report
  • Klaria Pharma issued a correction to its Q2 2026 interim report, reiterating key financial metrics for the quarter.
  • Profit after tax was SEK -12.9 million, earnings per share SEK -0.05, operating cash flow SEK -14.8 million.
  • Liquid assets totaled SEK 8.5 million at June 30, group equity was SEK -33.6 million.
  • For January–June 2026, net sales were SEK 0.1 million, profit after tax SEK -21.5 million, earnings per share SEK -0.09.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20260831:BIT:4545:0) on August 31, 2026, and is solely responsible for the information contained therein.